08.03.26 -- CGT Modality, Hybrid Models, And What To Keep In-House

Rapid cell therapy development requires early planning for scalability and standardized, inspection-ready operations to satisfy regulatory expectations and prevent rework.

Streamlined AAV transient transfection platforms de-risk your route to IND filing while cutting down on time-consuming process development and analytical complexity.

Platform-based manufacturing uses standardized, pre-qualified workflows and analytics that reduce variability, simplify regulatory submissions, and accelerate the path to commercial success.

Traditional plasmid DNA manufacturing introduces biological impurities and structural variability that lower viral titers. Transitioning to cell-free synthetic DNA platforms ensures sequence fidelity.

Overcome adenoviral scale-up challenges with a design-to-scale manufacturing framework that optimizes cell growth, boosts vector productivity, and supports reliable clinical supply.

Prioritize operational efficiency over early-stage flexibility to scale advanced therapies. Standardized workflows and qualified shipping lanes reduce variability for predictable late-phase success.

Adopting distributed manufacturing models lowers production costs, resolves infrastructure hurdles, and expands global patient access to advanced cell therapies.